https://www.accc.gov.au
The ACCC is seeking views on a divestment undertaking offered by
The ACCC has preliminary competition concerns in relation to worming treatments commonly used for cats and dogs, as the acquisition would combine ownership of
Similarly, the ACCC also identified preliminary concerns due to the consolidation in sheep lice products.
The proposed divestment undertaking would require
"The release of the proposed divestment undertaking for public comment should not be interpreted as a signal that the ACCC will ultimately accept the undertaking and clear the transaction. We are following our usual practice of publicly consulting on a proposed divestment package," ACCC Deputy Chair
"We are seeking feedback from industry participants on whether the divestment package will be sufficient to address any competition concerns arising from the proposed acquisition."
The ACCC now seeks views from market participants on whether the proposed undertaking would be likely to alleviate competition concerns in sheep lice treatments, and intestinal worming treatments for companion animals. Parties wishing to make a submission should do so by
More information is available on the ACCC website at
Background
Both Bayer and
Bayer's sheep lice products include Avenge, Piranha and Viper. These products compete with
.
(C) 2020 M2 COMMUNICATIONS, source